LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.78 -1.14

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.44

Max

75.94

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+26.7% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.3B

12B

Ankstesnė atidarymo kaina

75.92

Ankstesnė uždarymo kaina

74.78

Naujienos nuotaikos

By Acuity

50%

50%

146 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-11 19:18; UTC

Pagrindinės rinkos jėgos

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

2026-03-11 23:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-11 23:54; UTC

Rinkos pokalbiai

Nikkei May Decline on Energy Costs Concerns -- Market Talk

2026-03-11 23:51; UTC

Rinkos pokalbiai

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

2026-03-11 23:41; UTC

Rinkos pokalbiai

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

2026-03-11 23:37; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

2026-03-11 23:17; UTC

Svarbiausios naujienos

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

2026-03-11 23:17; UTC

Svarbiausios naujienos

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

2026-03-11 22:29; UTC

Rinkos pokalbiai

Australia Shares Set to Fall in Early Trade -- Market Talk

2026-03-11 21:47; UTC

Uždarbis

Liontown Resources: Market Tailwinds Strengthening Outlook

2026-03-11 21:46; UTC

Uždarbis

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

2026-03-11 21:45; UTC

Uždarbis

Liontown Resources Says FY26 Guidance Unchanged

2026-03-11 21:45; UTC

Uždarbis

Liontown Resources 1H Unit Operating Costs A$985/Ton

2026-03-11 21:44; UTC

Uždarbis

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

2026-03-11 21:43; UTC

Uždarbis

Liontown Resources 1H Revenue A$207.5 Million

2026-03-11 21:43; UTC

Uždarbis

Liontown Resources 1H Net Loss A$184 Million

2026-03-11 21:12; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

2026-03-11 21:10; UTC

Uždarbis

Vista Gold FY25 Loss $7.5M >VGZ

2026-03-11 21:10; UTC

Uždarbis

Vista Gold FY25 Loss/Shr 6c >VGZ

2026-03-11 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-11 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-11 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Papa John's Draws Fresh Takeover Interest -- 2nd Update

2026-03-11 20:26; UTC

Uždarbis

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

2026-03-11 20:19; UTC

Svarbiausios naujienos

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

2026-03-11 20:15; UTC

Uždarbis

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

2026-03-11 20:12; UTC

Svarbiausios naujienos

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

2026-03-11 19:31; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

2026-03-11 19:01; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

2026-03-11 18:59; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

2026-03-11 18:43; UTC

Svarbiausios naujienos

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

26.7% į viršų

12 mėnesių prognozė

Vidutinis 95.86 USD  26.7%

Aukščiausias 110 USD

Žemiausias 72 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

12

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

146 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat